Synthesis and Biological Evaluation of Harmirins, Novel Harmine-Coumarin Hybrids as Potential Anticancer Agents.
antiproliferative activity
cell cycle analysis
coumarin
harmine
triazole
β-carboline
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
27 Oct 2021
27 Oct 2021
Historique:
received:
01
10
2021
revised:
24
10
2021
accepted:
25
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
As cancer remains one of the major health burdens worldwide, novel agents, due to the development of resistance, are needed. In this work, we designed and synthesized harmirins, which are hybrid compounds comprising harmine and coumarin scaffolds, evaluated their antiproliferative activity, and conducted cell localization and cell cycle analysis experiments. Harmirins were prepared from the corresponding alkynes and azides under mild reaction conditions using Cu(I) catalyzed azide-alkyne cycloaddition, leading to the formation of the 1
Identifiants
pubmed: 34770906
pii: molecules26216490
doi: 10.3390/molecules26216490
pmc: PMC8587047
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Coumarins
0
Harmine
4FHH5G48T7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Croatian Science Foundation
ID : UIP-2017-05-5160
Organisme : Croatian Science Foundation
ID : Young researcher's career development project - training of doctoral students
Références
Bioorg Med Chem Lett. 2011 Aug 15;21(16):4784-7
pubmed: 21752645
Curr Med Chem. 2007;14(17):1829-52
pubmed: 17627520
Bioorg Chem. 2016 Feb;64:42-50
pubmed: 26657602
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4783-6
pubmed: 22704238
Adv Cancer Res. 2016;129:51-88
pubmed: 26916001
Eur J Med Chem. 2018 Jan 20;144:398-409
pubmed: 29288941
PLoS One. 2012;7(12):e52162
pubmed: 23300602
Org Biomol Chem. 2015 Oct 7;13(37):9528-50
pubmed: 26284434
J Enzyme Inhib Med Chem. 2016;31(sup1):23-33
pubmed: 27028352
Int J Oncol. 2019 Jun;54(6):1995-2004
pubmed: 31081045
Drug Discov Today. 2009 May;14(9-10):516-22
pubmed: 19429512
Eur J Med Chem. 2015 Aug 28;101:476-95
pubmed: 26188907
Curr Top Med Chem. 2019;19(19):1694-1711
pubmed: 31237210
Molecules. 2020 Sep 23;25(19):
pubmed: 32977642
Molecules. 2019 Sep 18;24(18):
pubmed: 31540345
Eur J Med Chem. 2021 Nov 15;224:113687
pubmed: 34274829
RSC Med Chem. 2021 Mar 24;12(5):730-750
pubmed: 34124672
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Med Chem. 2012 Jan 12;55(1):403-13
pubmed: 22136433
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Onco Targets Ther. 2019 Jun 12;12:4585-4593
pubmed: 31354292
Bioorg Med Chem Lett. 2014 Feb 1;24(3):799-807
pubmed: 24418772
Eur J Med Chem. 2021 Apr 15;216:113321
pubmed: 33684825
Eur J Med Chem. 2018 Jan 20;144:557-571
pubmed: 29289881
Eur J Med Chem. 2020 Feb 1;187:111927
pubmed: 31812035
Cancers (Basel). 2020 Jul 19;12(7):
pubmed: 32707666
Sci Rep. 2016 Sep 14;6:33204
pubmed: 27625151